Beta Bionics (Nasdaq:BBNX) today became the latest company to announce an updated automated insulin delivery integration with Abbott (NYSE: ABT) .
Our sister site, Drug Delivery Business News, reports today that the company agreed to pair its iLet bionic pancreas system with Abbott’s future dual sensor. That sensor — yet to hit the market — would continuously monitor glucose and ketone levels.
This marks the third such integration for the Abbott dual sensor. The company already struck deals with Sequel Med Tech and Tandem Diabetes Care to integrate the sensor with their automated insulin delivery systems.
The iLet system currently already supports the Abbott FreeStyle Libre 3 Plus continuous glucose monitor (CGM). Abbott’s future sensor is built on the same form factor as the Libre 3 Plus system. Beta Bionics says the integration further extends the collaboration between companies.
Get the full story at our sister site, Drug Delivery Business News.
